Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.
Identifieur interne : 003304 ( PubMed/Corpus ); précédent : 003303; suivant : 003305Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.
Auteurs : Bruno Vergès ; Martin Adiels ; Jan Boren ; Peter Hugh Barrett ; Gerald F. Watts ; Dick Chan ; Laurence Duvillard ; Sanni Söderlund ; Niina Matikainen ; Juhani Kahri ; Isabelle Robin ; Marja-Riitta TaskinenSource :
- The Journal of clinical endocrinology and metabolism [ 1945-7197 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : Apolipoproteins, Lipoproteins, HDL, Lipoproteins, VLDL.
- metabolism : Adipose Tissue, Liver, Obesity, Abdominal.
- Adult, Aged, Female, Humans, Male, Middle Aged.
Abstract
Low plasma high-density lipoprotein (HDL) cholesterol is a major abnormality in abdominal obesity. This relates due to accelerated HDL catabolism, but the underlying mechanism requires further elucidation. The relationships between HDL catabolism and other variables that may be modified in abdominal obesity, such as very low-density lipoprotein (VLDL) subspecies (VLDL1, VLDL2) kinetics, liver fat, or visceral adiposity, remain to be investigated.
DOI: 10.1210/jc.2014-2365
PubMed: 25077901
Links to Exploration step
pubmed:25077901Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.</title><author><name sortKey="Verges, Bruno" sort="Verges, Bruno" uniqKey="Verges B" first="Bruno" last="Vergès">Bruno Vergès</name><affiliation><nlm:affiliation>Departments of Endocrinology-Diabetology (B.V., I.R.) and Medical Biology (L.D.), University Hospital, and INSERM CRI 866 (B.V., L.D.), 21000 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (H.B., G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Central Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, and Department of Medicine (N.M., J.K.), Helsinki University Central Hospital, 00290 Helsinki, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Adiels, Martin" sort="Adiels, Martin" uniqKey="Adiels M" first="Martin" last="Adiels">Martin Adiels</name></author><author><name sortKey="Boren, Jan" sort="Boren, Jan" uniqKey="Boren J" first="Jan" last="Boren">Jan Boren</name></author><author><name sortKey="Barrett, Peter Hugh" sort="Barrett, Peter Hugh" uniqKey="Barrett P" first="Peter Hugh" last="Barrett">Peter Hugh Barrett</name></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name></author><author><name sortKey="Chan, Dick" sort="Chan, Dick" uniqKey="Chan D" first="Dick" last="Chan">Dick Chan</name></author><author><name sortKey="Duvillard, Laurence" sort="Duvillard, Laurence" uniqKey="Duvillard L" first="Laurence" last="Duvillard">Laurence Duvillard</name></author><author><name sortKey="Soderlund, Sanni" sort="Soderlund, Sanni" uniqKey="Soderlund S" first="Sanni" last="Söderlund">Sanni Söderlund</name></author><author><name sortKey="Matikainen, Niina" sort="Matikainen, Niina" uniqKey="Matikainen N" first="Niina" last="Matikainen">Niina Matikainen</name></author><author><name sortKey="Kahri, Juhani" sort="Kahri, Juhani" uniqKey="Kahri J" first="Juhani" last="Kahri">Juhani Kahri</name></author><author><name sortKey="Robin, Isabelle" sort="Robin, Isabelle" uniqKey="Robin I" first="Isabelle" last="Robin">Isabelle Robin</name></author><author><name sortKey="Taskinen, Marja Riitta" sort="Taskinen, Marja Riitta" uniqKey="Taskinen M" first="Marja-Riitta" last="Taskinen">Marja-Riitta Taskinen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25077901</idno><idno type="pmid">25077901</idno><idno type="doi">10.1210/jc.2014-2365</idno><idno type="wicri:Area/PubMed/Corpus">003304</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003304</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.</title><author><name sortKey="Verges, Bruno" sort="Verges, Bruno" uniqKey="Verges B" first="Bruno" last="Vergès">Bruno Vergès</name><affiliation><nlm:affiliation>Departments of Endocrinology-Diabetology (B.V., I.R.) and Medical Biology (L.D.), University Hospital, and INSERM CRI 866 (B.V., L.D.), 21000 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (H.B., G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Central Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, and Department of Medicine (N.M., J.K.), Helsinki University Central Hospital, 00290 Helsinki, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Adiels, Martin" sort="Adiels, Martin" uniqKey="Adiels M" first="Martin" last="Adiels">Martin Adiels</name></author><author><name sortKey="Boren, Jan" sort="Boren, Jan" uniqKey="Boren J" first="Jan" last="Boren">Jan Boren</name></author><author><name sortKey="Barrett, Peter Hugh" sort="Barrett, Peter Hugh" uniqKey="Barrett P" first="Peter Hugh" last="Barrett">Peter Hugh Barrett</name></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name></author><author><name sortKey="Chan, Dick" sort="Chan, Dick" uniqKey="Chan D" first="Dick" last="Chan">Dick Chan</name></author><author><name sortKey="Duvillard, Laurence" sort="Duvillard, Laurence" uniqKey="Duvillard L" first="Laurence" last="Duvillard">Laurence Duvillard</name></author><author><name sortKey="Soderlund, Sanni" sort="Soderlund, Sanni" uniqKey="Soderlund S" first="Sanni" last="Söderlund">Sanni Söderlund</name></author><author><name sortKey="Matikainen, Niina" sort="Matikainen, Niina" uniqKey="Matikainen N" first="Niina" last="Matikainen">Niina Matikainen</name></author><author><name sortKey="Kahri, Juhani" sort="Kahri, Juhani" uniqKey="Kahri J" first="Juhani" last="Kahri">Juhani Kahri</name></author><author><name sortKey="Robin, Isabelle" sort="Robin, Isabelle" uniqKey="Robin I" first="Isabelle" last="Robin">Isabelle Robin</name></author><author><name sortKey="Taskinen, Marja Riitta" sort="Taskinen, Marja Riitta" uniqKey="Taskinen M" first="Marja-Riitta" last="Taskinen">Marja-Riitta Taskinen</name></author></analytic><series><title level="j">The Journal of clinical endocrinology and metabolism</title><idno type="eISSN">1945-7197</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adipose Tissue (metabolism)</term><term>Adult</term><term>Aged</term><term>Apolipoproteins (metabolism)</term><term>Female</term><term>Humans</term><term>Lipoproteins, HDL (metabolism)</term><term>Lipoproteins, VLDL (metabolism)</term><term>Liver (metabolism)</term><term>Male</term><term>Middle Aged</term><term>Obesity, Abdominal (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Apolipoproteins</term><term>Lipoproteins, HDL</term><term>Lipoproteins, VLDL</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adipose Tissue</term><term>Liver</term><term>Obesity, Abdominal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Low plasma high-density lipoprotein (HDL) cholesterol is a major abnormality in abdominal obesity. This relates due to accelerated HDL catabolism, but the underlying mechanism requires further elucidation. The relationships between HDL catabolism and other variables that may be modified in abdominal obesity, such as very low-density lipoprotein (VLDL) subspecies (VLDL1, VLDL2) kinetics, liver fat, or visceral adiposity, remain to be investigated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25077901</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>06</Day></DateCreated><DateCompleted><Year>2015</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation></Journal><ArticleTitle>Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.</ArticleTitle><Pagination><MedlinePgn>4281-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2014-2365</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Low plasma high-density lipoprotein (HDL) cholesterol is a major abnormality in abdominal obesity. This relates due to accelerated HDL catabolism, but the underlying mechanism requires further elucidation. The relationships between HDL catabolism and other variables that may be modified in abdominal obesity, such as very low-density lipoprotein (VLDL) subspecies (VLDL1, VLDL2) kinetics, liver fat, or visceral adiposity, remain to be investigated.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our aim was to study the associations between HDL apolipoprotein (apo)-A-I fractional catabolic rate (FCR) and the kinetics of VLDL subspecies and estimates of liver and visceral and sc fat.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We carried out a multicenter in vivo kinetic study using stable isotopes (deuterated leucine and glycerol) in 62 individuals with abdominal obesity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a multivariate analysis, among the morphological and biological parameters that may predict apoA-I FCR, liver fat (β = .400, P = .003), and VLDL1-apoB (β = .307, P = .020) were independently associated with apoA-I FCR. In a multivariate analysis, among the kinetic parameters, VLDL1-triglycerides (TGs) indirect FCR (β = -.357, P = .001), VLDL1-TG production rate (β = 0.213, P = .048), and apoA-II FCR (β = .667, P < .0001) were independently associated with apoA-I FCR. After adjustment for VLDL1-TG production rate, liver fat was no more correlated with apoA-I FCR. No association between apoA-I FCR and visceral fat was observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We show that VLDL1 is an important independent determinant of apoA-I FCR and more precisely that apoA-I FCR is independently associated with both catabolism and the production of VLDL1-TG. In addition, we show an association between liver fat and apoA-I FCR that is mostly mediated by VLDL1-TG production. These data indicate that, in abdominal obesity, dysfunctional VLDL1 metabolism is an important modulator of HDL apoA-I catabolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vergès</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departments of Endocrinology-Diabetology (B.V., I.R.) and Medical Biology (L.D.), University Hospital, and INSERM CRI 866 (B.V., L.D.), 21000 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (H.B., G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Central Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, and Department of Medicine (N.M., J.K.), Helsinki University Central Hospital, 00290 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adiels</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Boren</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Peter Hugh</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Gerald F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Duvillard</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Söderlund</LastName><ForeName>Sanni</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Matikainen</LastName><ForeName>Niina</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kahri</LastName><ForeName>Juhani</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Robin</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Taskinen</LastName><ForeName>Marja-Riitta</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00408148</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001053">Apolipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008079">Lipoproteins, VLDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001053" MajorTopicYN="N">Apolipoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008079" MajorTopicYN="N">Lipoproteins, VLDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056128" MajorTopicYN="N">Obesity, Abdominal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25077901</ArticleId><ArticleId IdType="doi">10.1210/jc.2014-2365</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003304 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003304 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25077901
|texte= Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25077901" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |